Hyperphosphatemia Vascular calcification , Arterial stiffness , Endothelial dysfunction Atherosclerosis , Arteriolosclerosis , Arterial thickening Left ventricular hypertrophy , Cardiac interstitial fibrosis Cardiovascular disease myocardial infarction , ischemic infarction stroke , peripheral vascu

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Kidney disease

  2019influential reference
• Vascular Calcification in Patients with End-Stage Renal Disease

  2015cited by this paper
• Phosphorus-containing food additives: An insidious danger for people with chronic kidney disease

  2012cited by this paper
• Coronary Artery Calcification and Coronary Disease

  2012cited by this paper
• Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.

  2011cited by this paper
• FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.

  2010cited by this paper
• Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

  2010cited by this paper
• Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community.

  2009cited by this paper
• Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

  2009cited by this paper
• Fibroblast Growth Factor 23: A Possible Cause of Left Ventricular Hypertrophy in Hemodialysis Patients

  2009influential reference
• Regulation of phosphate transport in proximal tubules

  2009cited by this paper
• Dietary phosphorus acutely impairs endothelial function

  2009cited by this paper
• Phosphorus binders and survival on hemodialysis.

  2009influential reference
• Dietary phosphorus acutely impairs endothelial function.

  2009cited by this paper
• Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

  2008cited by this paper
• Increased inorganic phosphate induces human endothelial cell apoptosis in vitro.

  2008cited by this paper
• Bone and Mineral Metabolism and Disease

  2008cited by this paper
• Hyperphosphatemia of chronic kidney disease.

  2008cited by this paper
• A primer for the prescription of short‐daily and nocturnal hemodialysis

  2008cited by this paper
• [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].

  2008influential reference
• A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate*

  2007cited by this paper
• Hidden Phosphorus: Where Do We Go From Here?

  2007cited by this paper
• Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.

  2007cited by this paper
• New Aspect of Renal Phosphate Reabsorption: The Type IIc Sodium-Dependent Phosphate Transporter

  2007cited by this paper
• The vitamin D receptor.

  2007cited by this paper
• K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?

  2007influential reference
• A novel function of phosphate-mediated intracellular signal transduction pathways.

  2006cited by this paper
• Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men.

  2006cited by this paper
• FGF-23 and sFRP-4 in Chronic Kidney Disease and Post-Renal Transplantation

  2006cited by this paper
• Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor?

  2006cited by this paper
• Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.

  2006influential reference
• Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.

  2006influential reference
• Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.

  2006influential reference
• Long-Term Efficacy and Tolerability of Lanthanum Carbonate: Results from a 3-Year Study

  2005cited by this paper
• Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

  2005cited by this paper
• Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

  2005cited by this paper
• Sevelamer Hydrochloride and Calcium Bicarbonate Reduce Serum Fibroblast Growth Factor 23 Levels in Dialysis Patients

  2005cited by this paper
• [New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments].

  2005cited by this paper
• Mild hyperphosphatemia and mortality in hemodialysis patients.

  2005cited by this paper
• Fibroblast Growth Factor 23 and Its Receptors

  2005cited by this paper
• Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice.

  2005cited by this paper
• Regulation of phosphorus homeostasis by the type iia na/phosphate cotransporter.

  2005cited by this paper
• FGF23 and disorders of phosphate homeostasis.

  2005cited by this paper
• Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.

  2005influential reference
• Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

  2004influential reference
• Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

  2004cited by this paper
• Time and exercise improve phosphate removal in hemodialysis patients.

  2004cited by this paper
• Physiological regulation of renal sodium-dependent phosphate cotransporters.

  2004cited by this paper
• What have we learnt about the regulation of phosphate metabolism?

  2004cited by this paper
• Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease?

  2004cited by this paper
• FGF-23 in patients with end-stage renal disease on hemodialysis.

  2004cited by this paper
• Improving phosphate-binder therapy as a way forward.

  2004cited by this paper
• Intestinal Na-P(i) cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice.

  2004cited by this paper
• Regulation of cardiovascular calcification.

  2004cited by this paper
• FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis

  2003cited by this paper
• Bone metabolism and disease in chronic kidney disease

  2003influential reference
• Vascular calcification: in vitro evidence for the role of inorganic phosphate.

  2003cited by this paper
• European Guidelines for the Nutritional Care of Adult Renal Patients

  2003cited by this paper
• Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study.

  2003cited by this paper
• Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia.

  2003cited by this paper
• Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

  2003cited by this paper
• Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration.

  2003cited by this paper
• Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality.

  2003cited by this paper
• Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels.

  2003cited by this paper
• Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.

  2003influential reference
• Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study.

  2003cited by this paper
• A Kinetic Model of Inorganic Phosphorus Mass Balance in Hemodialysis Therapy

  2003cited by this paper
• Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function.

  2003cited by this paper
• Mediation of Unusually High Concentrations of 1,25-Dihydroxyvitamin D in Homozygous klotho Mutant Mice by Increased Expression of Renal 1α-Hydroxylase Gene.

  2002cited by this paper
• Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.

  2002influential reference
• Effects of excess calcium load on the cardiovascular system measured with electron beam tomography in end-stage renal disease.

  2002cited by this paper
• Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study.

  2002cited by this paper
• Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study.

  2002cited by this paper
• Age-dependent regulation of rat intestinal type IIb sodium-phosphate cotransporter by 1,25-(OH)(2) vitamin D(3).

  2002cited by this paper
• Vascular calcification and inorganic phosphate.

  2001cited by this paper
• Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients.

  2001cited by this paper
• Role of phosphorus in the pathogenesis of secondary hyperparathyroidism.

  2001cited by this paper
• National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure.

  2001influential reference
• Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure.

  2001influential reference
• Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors?

  2000cited by this paper
• Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.

  2000cited by this paper
• Alterations of Arterial Function in End-Stage Renal Disease

  2000cited by this paper
• Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.

  2000cited by this paper
• Molecular mechanisms of mammalian inorganic phosphate homeostasis.

  2000cited by this paper
• Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure.

  2000cited by this paper
• Proximal tubular phosphate reabsorption: molecular mechanisms.

  2000cited by this paper
• Phosphate regulation of vascular smooth muscle cell calcification.

  2000cited by this paper
• Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients.

  2000cited by this paper
• Atherosclerosis is an inflammatory disease

  1999cited by this paper
• Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease.

  1998cited by this paper
• Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism.

  1998cited by this paper
• Clinical epidemiology of cardiovascular disease in chronic renal disease.

  1998cited by this paper
• Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.

  1998cited by this paper
• C-reactive protein as an outcome predictor for maintenance hemodialysis patients.

  1998cited by this paper
• Nature of Variation in Diet

  1998cited by this paper
• Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.

  1997cited by this paper
• Mutation of the mouse klotho gene leads to a syndrome resembling ageing

  1997cited by this paper
• Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients.

  1996cited by this paper
• Changing phosphorus content of the U.S. diet: potential for adverse effects on bone.

  1996cited by this paper
• Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy.

  1992influential reference

• No citing papers are available for this paper.